D
퓨쳐켐
220100KOSDAQ의약품 제조업37.0 / 100
Reference Date: 2026-04-13
Financial Score11.5 / 40
News Sentiment12.5 / 25
Momentum3.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is low with sound financial health but ROE is below the industry average. Declined 13.9% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
FutureChem develops radiopharmaceuticals by researching peptides similar to proteins specifically expressed in certain diseases, offering diagnostic and therapeutic drugs. Key products include FC303 for prostate cancer diagnosis and FC705 for treatment, leveraging theranostics technology for personalized medicine. The company utilizes the sCUBE® automated synthesis system to achieve GMP-level manufacturing standards.
Number of Employees
94people
Average Salary
53.3M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 14.804.0Point
PBR
7.67Industry Average 1.040.0Point
7.4x industry avg (risky)
ROE
-20.50Industry Average 4.420.0Point
Well below industry avg
Debt Ratio
9.30Industry Average 11.984.0Point
In line with industry avg
Trend 2023~20253.5 / 10 points
Revenue Growth Rate
2.5 / 3
Avg ▲15.9% (2-year basis)
Operating Profit Growth Rate
1.0 / 3
Avg ▲2.8% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -15.5% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (18%, downtrend)
Current 18,760Won52-week high 34,20052-week low 15,200
1-month return1.0Point
1m -13.94% (falling)
Volume trend1.0Point
Volume decreasing
Detailed Disclosure
3 totalPositive 0Neutral 3Negative 0
- Neutral정기주주총회결과2026-03-26
- Neutral사업보고서 (2025.12)2026-03-18
- Neutral기타경영사항(자율공시) (자기사채(제3회 전환사채) 소각 결정)2026-03-18